Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) said its anti-HER2 drug HLX22 was granted orphan drug designation by the European Commission.
The drug is used for gastric and breast cancer treatment.
Further clinical trials and regulatory approvals are required before commercialization.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.